Clinical Trials Logo
  1. Home
  2. Blood Cancer
  3. NCT04390542

Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy

Blood Cancer Clinical Trial

Official title:
A Pilot Study Evaluating Feasibility, Acceptability, Usability, Satisfaction and Preliminary Efficacy of an Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy

Clinical Trial Summary

The purpose of this study is to determine which of two approaches is helpful to support caregivers of patients undergoing Hematopoietic Stem Cell Transplant (HSCT) or Chimeric Antigen Receptors (CAR) T-cell therapy at Seidman Cancer Center. This study will take start before you begin treatment until 2 months after your hospital discharge.

Clinical Trial Description

This is a two-group, randomized pilot study to test the feasibility, acceptability, usability, satisfaction and preliminary efficacy of a behavioral (psychoeducation) intervention, as compared to a usual care (information from healthcare providers) control group, on caregiver outcomes. The control and intervention groups will receive the standard University Hospitals Seidman Cancer Center (SCC) binder of relevant information regarding care of the patient undergoing HSCT or CAR T-cell therapy. This information will be given to the caregiver by the health care provider. In addition, the intervention group will receive 6 individual sessions with an interventionist during all phases of HSCT or CAR T-cell therapy. The independent variable is group assignment. The primary objective of this study is to explore the feasibility and acceptability of a psycho-educational intervention designed for caregivers of patients receiving HSCT (allogenic or autologous) or CAR T-cell therapy. The secondary objective of this study is to explore the usability, satisfaction and preliminary efficacy of a psycho-educational intervention designed for caregivers of patients receiving HSCT (allogenic or autologous) or CAR T-cell therapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04390542
Study type Interventional
Source Case Comprehensive Cancer Center
Contact
Status Withdrawn
Phase N/A
Start date June 2021
Completion date September 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT03654404 - A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients N/A
Recruiting NCT06116032 - Immune Profiling for Cancer Immunotherapy Response
Recruiting NCT04955938 - A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Phase 1
Recruiting NCT06119685 - IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers Phase 1/Phase 2
Not yet recruiting NCT05391490 - Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies Phase 1
Recruiting NCT05709522 - Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
Completed NCT00186225 - Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors N/A
Active, not recruiting NCT05147311 - Positive Psychology Intervention In HSCT N/A
Recruiting NCT04372524 - Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
Completed NCT01957579 - A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies Phase 1
Completed NCT00185640 - Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies Phase 2
Completed NCT04419623 - A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer Phase 1
Recruiting NCT04806295 - The Leukemia and Lymphoma Society (LLS) National Research Registry
Recruiting NCT05873205 - Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation Phase 2
Completed NCT00962494 - Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors Phase 2
Completed NCT00185796 - TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Phase 2
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Recruiting NCT05692713 - Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
Recruiting NCT06250595 - European Rare Blood Disorders Platform (ENROL)